Changchun High-Tech Industries (000661.SZ) announced on November 28th that, according to the notice issued by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security on the issuance of the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (Medical Insurance Development [2024] No. 33), Changchun High-Tech Industries (Group) Co., Ltd., a holding subsidiary of Changchun Jinsai Pharmaceutical Co., Ltd., has included Jinsai Xin Progesterone Injection (Ⅱ) (1.112ml:25mg) in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog.
The inclusion of Jinsai Xin Progesterone Injection (Ⅱ) in the 2024 National Medical Insurance Catalog marks Jinsai Xin Progesterone Injection (Ⅱ) as the first nationally negotiated pharmaceutical product in the field of assisted reproduction.